Clinical Trial

Verge Labs' new AI model promises to predict brain activity from a blood draw, potentially upending the costly and failure-prone world of neurology R&D.

Biotech firm ProJenX reports its novel ALS drug, prosetin, is safe and hits key targets in early trials, offering a new beacon of hope for the disease.

The appointment of drug development veteran Dr. Aaron Koenig at Syremis Therapeutics is more than a new hire; it's a strategic play in the high-stakes race to redefine mental health treatment.

A simple blood test for lung cancer completes key validation, signaling potential disruption for the diagnostics market and major savings for healthcare systems.

Preliminary data from a randomized trial suggests a personalized medicine approach can reverse cognitive decline, offering a glimmer of hope beyond slowing the disease.

Verastem Oncology is preparing to show its hand with VS-7375, a novel dual-action KRAS G12D inhibitor. Can its unique science disrupt a crowded market?

New Phase 3 data for Takeda's oveporexton shows it treats the root cause of narcolepsy, not just symptoms. A key FDA decision looms this year.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

New data reveals elevated cortisol in over 75% of hard-to-treat diabetes patients, paving the way for a novel drug to tackle treatment resistance.

A new partnership between Klick Labs and Mayo Clinic aims to detect disease using your voice. But what does this mean for the future of our health systems?

A single AML patient's journey to a stem cell transplant after treatment with CER-1236 offers a glimmer of hope, but is it a breakthrough or a mirage?

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.

Legend Biotech's stunning trial results for an 'in vivo' CAR-T therapy could make advanced cancer treatment faster, safer, and accessible to all.

Phase 1 data for Marea Therapeutics’ MAR002 suggests a potential new era for acromegaly treatment, promising better control with far fewer injections.

With a landmark therapy for Sanfilippo Syndrome nearing the FDA, Spruce adds veteran marketing and finance chiefs. A look at the talent behind the transition.

Amid new Ebola fears, one biotech's rapid C1 platform promises 15-day biologics, eyeing a $25B market beyond just pandemic response. But can it deliver?

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

A missed clinical trial endpoint is often the end. For Elicio Therapeutics, a deeper data dive reveals a potential path forward for a high-need patient group.

Tiziana Life Sciences’ chairman just increased his massive stake. We analyze if this is a vote of confidence in its novel MS drug or a risky bet on a fragile biotech.

New data reveals an oral drug can halt severe hereditary angioedema attacks in minutes, promising a future free from needles and fear for thousands.